Instrument Business Outlook (IBO):
On May 19, Shimadzu Corporation has invested in ChromaCode Inc. (ChromaCode), a startup with technology to expand genetic testing, through its corporate venture capital (CVC) fund, Shimadzu Future Innovation Fund L.P. (Shimadzu FIF). This is Shimadzu FIF’s first investment.
ChromaCode is a startup that expands the number of target genes available in existing PCR with its proprietary reagents and analysis software to enable high-precision “multiplex PCR”(High Definition PCR, HDPCR) *. PCR is a technique that replicates and amplifies DNA with specific genetic information to test for the presence of a target gene. ChromaCode’s HDPCR is a platform technology that can be applied to a wide range of genetic tests, including cancer and infectious diseases, and is expected to expand the scope of PCR testing.